Previous close | 0.1200 |
Open | 0.1000 |
Bid | 0.1000 x N/A |
Ask | 0.1300 x N/A |
Day's range | 0.1000 - 0.1200 |
52-week range | 0.0800 - 0.2900 |
Volume | |
Avg. volume | 11,800 |
Market cap | 12.252M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1400 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
ARCpoint ( CVE:ARC ) First Quarter 2024 Results Key Financial Results Revenue: US$1.61m (down 5.8% from 1Q 2023). Net...
Greenville, South Carolina, May 23, 2024 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) a leading US-based franchise system providing drug testing, alcohol screening, DNA and direct to consumer (“DTC”) clinical lab testing services, announces that it will host a conference call at 11am Eastern time, Friday, May 24, 2024 to review the Company’s Q1 financial results for the period ending March 31, 2024. The dial-in number for the conference call is as follows: Canada /
ARCpoint ( CVE:ARC ) Full Year 2023 Results Key Financial Results Revenue: US$6.67m (down 39% from FY 2022). Net loss...